Manuscripts
Showing 1543 manuscripts.
Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Citation
Kunjal Patel, Miguel A. Hernan, Paige L. Williams, John D. Seeger, Kenneth McIntosh, Russell B. Van Dyke, George Seage. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.. Clinical Infectious Diseases. 2008. 46: 507 - 515. PMID: 18199042Year
2008
Journal
Clinical Infectious Diseases
Pharmacokinetics of high-dose lopinavir/ritonavir with and without saquinavir or non-nucleoside reverse transcriptase inhibitors in HIV infected pediatric and adolescent patients previously treated with protease inhibitors ¿ study PACTG P1038.
Citation
Brian Robbins, Edmund Capparelli, Ellen Gould Chadwick, Ram Yogev, Leslie Serchuck, Carol J. Worrell, Carmelita Alvero, Terence Fenton, Barbara E. Heckman, Stephen Ira Pelton, Grace M. Aldrovandi, William Borkowsky, John H. Rodman, Peter Havens. Pharmacokinetics of high-dose lopinavir/ritonavir with and without saquinavir or non-nucleoside reverse transcriptase inhibitors in HIV infected pediatric and adolescent patients previously treated with protease inhibitors ¿ study PACTG P1038.. Antimicrobial Agents and Chemotherapy. 2008. 52: 3276-83. PMID: 18625762Year
2008
Journal
Antimicrobial Agents and Chemotherapy
Study
P1038
Efficacy, safety and tolerability of tipranavir co-administered with ritonavir in HIV-1-infected children and adolescents.
Citation
Juan Carlos Salazar, Pedro E. Cahn, Ram Yogev, Marinella Della Negra, Guido Castelli-Gattinara, Claudia Fortuny, Patricia M. Flynn, Carlo Giaquinto, Ping Ruan, Elizabeth (Betsy) Smith, Jaromir Mikl, Hernan Valdez, Ante Jelaska. Efficacy, safety and tolerability of tipranavir co-administered with ritonavir in HIV-1-infected children and adolescents.. AIDS. 2008. 22: 1789-98. PMID: 18753862Year
2008
Journal
AIDS
Study
P1051
Toxicities associated with dual NRTI regimens in HIV-infected children
Citation
Russell B. Van Dyke, Lu Wang, Paige L. Williams. Toxicities associated with dual NRTI regimens in HIV-infected children. Journal of Infectious Diseases. 2008. 198: 1599-608. PMID: 19000014Year
2008
Journal
Journal of Infectious Diseases
Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral Treatment Switch After Initial Nonsuppressive Highly Active Antiretroviral Therapy
Citation
Allison George Agwu, Jane C. Lindsey, Kimberly Ferguson, Haili Zhang, Stephen A. Spector, Bret J. Rudy, Steven D. Douglas, Patricia M. Flynn, Deborah Persaud. Analyses of HIV-1 Drug-Resistance Profiles Among Infected Adolescents Experiencing Delayed Antiretroviral Treatment Switch After Initial Nonsuppressive Highly Active Antiretroviral Therapy. AIDS Patient Care and STDs. 2008. 22: 545-52. PMID: 18479228Year
2008
Journal
AIDS Patient Care and STDs
Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C
Citation
Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C. Journal of Clinical Microbiology. 2008. 46: 2945-9. PMID: 18614660Year
2008
Journal
Journal of Clinical Microbiology
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics
Citation
Marlene Smurzynski, Ann C. Collier, Susan L. Koletar, Ronald J. Bosch, Kunling Wu, Barbara Bastow, Constance A. Benson. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clinical Trials. 2008. 9: 269-82.Year
2008
Journal
HIV Clinical Trials
Improved measures of quality of life, lipid profile and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170
Citation
Daniel J. Skiest, Amy Krambrink, Zhaohui Su, Kevin R. Robertson, David M. Margolis. Improved measures of quality of life, lipid profile and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. Journal of Acquired Immune Deficiency Syndromes. 2008. 49: 377-83.Year
2008
Journal
Journal of Acquired Immune Deficiency Syndromes
The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients
Citation
Lisa M. Demeter, Lisa Mukherjee, Robin DiFrancesco, Hongyu Jiang, Robert DiCenzo, Barbara Bastow, Alex R. Rinehart, Gene D. Morse, Mary Albrecht. The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients. HIV Clinical Trials. 2008. 9: 61-72.Year
2008
Journal
HIV Clinical Trials
The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy
Citation
Jeffrey A. Canter, David W. Haas, Asha R. Kallianpur, Marylyn D. Ritchie, Gregory K. Robbins, Robert Shafer, David B. Clifford, Deborah G. Murdock, Todd Hulgan. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics. 2008. 8: 71-7.Year
2008
Journal
Pharmacogenomics